Cooper Companies (The)
COOBusiness Model
Step 01 — Business Overview: The Cooper Companies (COO)
Research Path: Filings + consensus (no earnings transcripts) Date: 2026-06-04 Fiscal Year End: October 31
Section 1 — Executive Summary
The Cooper Companies, Inc. (NASDAQ: COO) is a global specialty medical device company organized around two distinct but complementary healthcare franchises: CooperVision, the world's second-largest manufacturer of soft contact lenses, and CooperSurgical, a leading supplier of instruments, consumables, and clinical services for in vitro fertilization (IVF) and women's health. In FY2025 (ended October 31, 2025), COO generated approximately $4.09B in net revenue, with CooperVision contributing ~$2.74B (~67% of total) and CooperSurgical ~$1.35B (~33%). [S1] The company's value proposition rests on the recurring, consumable nature of its products: contact lens wearers repurchase lenses on a daily, monthly, or annual basis for years to decades, while fertility clinics consume IVF media, disposables, and instruments per procedure cycle. This consumable-driven model produces predictable revenue streams with limited single-event concentration risk, and COO's clinical brand equity among eye care professionals (ECPs) and fertility specialists creates durable customer retention. At approximately $60/share and ~$11.77B market cap as of late 2025, COO trades near a multi-year trough despite continued top-line growth and a pending strategic review of CooperSurgical catalyzed by activist investors Jana Partners and Browning West. [S2]
Section 2 — Business Model
COO generates revenue through the manufacture and sale of specialty medical devices and consumables sold primarily to healthcare professionals and institutions, not directly to end consumers.
CooperVision (CV) — ~67% of FY2025 Revenue CooperVision sells soft contact lenses to independent optometrists, ophthalmologists, optical chains, and online retailers who dispense or resell to patients. Revenue is product-only (no services component); the recurring purchase cycle is driven by lens type: daily disposables are replaced every day, monthly replacement lenses every 30 days, and toric/multifocal specialty lenses on similar cycles. The model resembles a razor/razorless consumable: once an ECP fits a patient on a specific lens modality and brand, the patient tends to repurchase the same SKU for years. Pricing power comes from CooperVision's specialty portfolio (torics and multifocals command a premium over commodity spherical lenses), its MiSight myopia management franchise (a prescriptive, clinician-managed product with no direct OTC substitute), and strong relationships with independent ECPs who prefer the breadth and clinical support of CooperVision's portfolio. [S1]
CooperSurgical (CS) — ~33% of FY2025 Revenue CooperSurgical addresses two sub-markets: (a) fertility/IVF and (b) OB/GYN consumables and office-based instruments. The IVF segment sells culture media, embryo transfer catheters, cryogenic storage products, genetic preimplantation testing (PGT) services, incubators, and laser systems to fertility clinics; consumables per IVF cycle create a procedure-linked recurring revenue stream. The OB/GYN segment includes PARAGARD (the only hormone-free, non-hormonal copper IUD approved in the US), office surgical instruments, and disposables sold to hospitals and OB/GYN practices. The 2022 acquisition of Generate Life Sciences added direct fertility clinic operations in the UK, Europe, and Latin America (a services revenue model distinct from device/media sales). [S1][S2]
Revenue Model Summary
| Revenue Type | Segment | Recurrence |
|---|---|---|
| Daily/monthly lens repurchase | CooperVision | High — weekly to monthly |
| MiSight pediatric lenses | CooperVision | High — annual fitting + monthly supply |
| IVF media + consumables | CooperSurgical | Moderate — per-cycle procedure-linked |
| PGT genomics services | CooperSurgical | Moderate — per-cycle |
| PARAGARD IUD | CooperSurgical | Low recurrence — single device per patient |
| Fertility clinic services | CooperSurgical | High — clinic operations |
| OB/GYN instruments | CooperSurgical | Low — capital/semi-capital |
Section 3 — Value-Chain Layer Map
CooperVision Value Chain
Raw materials (silicone hydrogel, HEMA polymers)
↓
COO manufacturing (UK, US, Puerto Rico, Hungary, Malaysia, Costa Rica)
↓
Distribution / warehouse network (regional)
↓
Eye care professionals (optometrists, ophthalmologists, optical chains)
↓
Patient fitting + prescription issuance
↓
Patient repurchase (through ECP office, mail-order, or online)
CooperVision occupies the manufacturing and brand layer; it does not own retail dispensing channels but maintains pull-through demand by investing in ECP education, clinical support, and practitioner loyalty programs. The company's relationship with independent ECPs — particularly in the US and UK — is a structural advantage over mass-market brands, as independent ECPs tend to prescribe based on clinical fit rather than promotional incentives from large retail chains. [S1]
CooperSurgical Value Chain
IVF media/instrument manufacturing (Trumbull CT + acquired facilities)
↓
Direct sales force → fertility clinics (hospitals + private IVF centers)
↓
Per-cycle consumable consumption (media, disposables, PGT kits)
[Generate Life Sciences: COO also OPERATES fertility clinics]
↓
OB/GYN instruments → distributor or direct → hospital/office
↓
PARAGARD → distributor → OB/GYN practice → patient insertion
CooperSurgical's value chain is more vertical than CooperVision's: the Generate Life Sciences acquisition made COO a direct operator of fertility clinics in addition to a supplier, capturing margin at the services layer. This creates an unusual dual role: supplier to clinic competitors while operating competing clinics. [S2]
Section 4 — Segment Detail
CooperVision
Product Portfolio
- MyDay Daily (spherical + toric): Premium silicone hydrogel daily; MyDay Toric is one of the industry's leading daily toric lenses, a historically under-served specialty modality
- Clariti (spherical, toric, multifocal): Value-tier silicone hydrogel daily, positioned for ECPs seeking an affordable daily alternative to Acuvue
- Biofinity (monthly/two-week): CooperVision's legacy monthly silicone hydrogel platform; high installed base generating predictable reorder revenue
- MiSight 1 Day: The only FDA-approved (2019) soft contact lens with a product labeling claim for myopia progression control in children aged 8–12. This is a franchise asset: pediatric patients are fitted and managed by optometrists; COO invests heavily in ECP training programs. MiSight commands a significant premium over standard daily spherical lenses. [S1]
- Specialty lenses: Extended range torics, multifocals for presbyopia; these are high-margin and difficult to replicate given fitting complexity
Geography (approximate FY2025 split): Americas (~40%), EMEA (~36%), Asia-Pacific (~24%) [GAP — exact percentages from segment filings; proportions estimated from prior-year disclosures]
Competitive Position vs. Peers
| Company | Global Rank | Key Brands | Daily Toric Strength |
|---|---|---|---|
| J&J Vision | #1 | Acuvue Oasys, Acuvue Vita | Strong (1-Day Acuvue Moist for Astigmatism) |
| CooperVision | #2 | MyDay, Clariti, Biofinity, MiSight | Very strong (MyDay Toric market leader in premium daily toric) |
| Alcon | #3 | DAILIES Total1, Precision1 | Growing |
| Bausch + Lomb | #4 | Biotrue, ULTRA | Weaker in torics |
CooperVision's differentiated position in daily torics and multifocals — segments that command pricing power — and its exclusive ownership of MiSight's myopia control franchise represent durable competitive advantages versus peers. J&J Vision benefits from scale but has less specialty lens focus; Alcon is investing aggressively in dailies but CooperVision maintains a head start in torics. [S2]
CooperSurgical
Product Portfolio
- PARAGARD: The only non-hormonal copper IUD approved in the US; long-term contraception (up to 10–12 years); sold through OB/GYN channels. A mature, cash-generative product facing volume headwinds from competition and label controversy.
- Genomics / PGT: Preimplantation Genetic Testing for aneuploidy (PGT-A) and monogenic disorders (PGT-M); sold as a service per IVF cycle through in-house genetic labs
- IVF Media + Consumables: Culture media for embryo development, embryo transfer catheters, cryopreservation media, biopsy kits, sperm preparation media
- Incubators + Capital Equipment: Embryo incubators (benchtop and time-lapse), laser systems for assisted hatching — higher-margin capital equipment with recurring media pull-through
- Fertility Services (Generate Life Sciences): Direct fertility clinic operations in the UK (The Fertility Partnership), Europe, and Latin America; revenue from IVF procedures billed to patients/NHS/private insurance
- OB/GYN Disposables (Cook Medical portfolio, acquired Nov 2023): Cervical ripening balloons, uterine manipulation instruments, minimally invasive surgical tools for gynecologic procedures
- obp Surgical (acquired Aug 2024): Single-use illuminated vaginal specula and procedural kits for OB/GYN offices
Competitive Position in IVF
| Company | Segment | Key Products |
|---|---|---|
| CooperSurgical / Vitrolife | IVF media/instruments | Tied for top-2 globally |
| Vitrolife | IVF culture media | Strong in Europe |
| Thermo Fisher (Fisher Scientific) | Lab consumables | Broad catalog, less IVF-specialized |
| FUJIFILM Irvine Scientific | Culture media | Growing share |
| Cook Medical (subsidiary of COO post-Nov 2023) | Catheters, OB/GYN | Now internal |
CooperSurgical has become one of the world's largest fertility-market participants through organic growth and acquisitions (Generate ~$1.6B in Nov 2022; Cook Medical surgical ~$875M in Nov 2023). However, integration costs, asset write-offs, and severance charges in FY2025 compressed CooperSurgical's operating margin to approximately 3%, well below historical levels and the mid-teens margins management has targeted. [S1][S2]
Section 5 — Strategic Priorities
1. CooperVision Daily Disposable + MiSight Growth Management's primary organic growth engine is the secular shift from monthly/two-week replacement lenses to daily disposables. CooperVision's MyDay platform (spherical + toric + multifocal) is the leading premium daily offering. MiSight is a multi-year growth story: the pediatric myopia management market is nascent but accelerating, and COO holds the only FDA-approved myopia control contact lens label claim. International expansion (particularly Asia-Pacific, where myopia prevalence is highest) is a top geographic priority. [S1]
2. CooperSurgical Margin Recovery FY2025 saw significant charges in CooperSurgical: asset write-offs and severance compressed segment operating margin to ~3%. Management's stated goal is to restore CooperSurgical to mid-teens operating margins through cost rationalization, integration completion of the Generate and Cook Medical acquisitions, and portfolio pruning of underperforming assets. [S1]
3. $2 Billion Share Buyback Authorization In response to activist pressure from Jana Partners and Browning West (both disclosed positions and pushed for a formal strategic review in December 2025), the Board authorized a $2B share repurchase program — a significant commitment relative to the ~$11.77B market cap. Strong insider buying by the CEO, CFO, COO, and directors ($2.52M combined, September–December 2025) signals management conviction at current prices. [S2]
4. CooperSurgical Strategic Review Jana Partners and Browning West have publicly advocated for a separation or sale of CooperSurgical to unlock the CooperVision multiple, which they argue is depressed by the conglomerate discount. Management has acknowledged the strategic review without committing to a separation. A divestiture of CooperSurgical (or the services/Generate sub-segment) would be a significant capital allocation event and potential re-rating catalyst for the remaining CooperVision entity, which could arguably be valued at a premium medtech multiple (comparable to Alcon at 20–25x forward earnings). [S2]
5. International Expansion in Specialty Lenses Toric and multifocal penetration remains significantly lower outside the US and UK; COO's geographic expansion into Asia-Pacific and emerging markets (particularly China, Japan, India) represents a long-runway organic growth lever.
Section 6 — Key Financials Summary Table
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| CooperVision Revenue | $2,265M | $2,419M | $2,609M | $2,744M |
| CooperSurgical Revenue | $779M | $1,010M | $1,286M | $1,349M |
| Total Revenue | $3,044M | $3,429M | $3,895M | $4,092M |
| YoY Revenue Growth | — | +12.6% | +13.6% | +5.1% |
| Gross Margin (approx.) | ~63% | ~65% | ~65% | ~65.5% |
| GAAP EPS (diluted) | [GAP — FY2022 EPS not confirmed] | [GAP] | [GAP] | [GAP] |
| Non-GAAP Forward P/E | — | — | — | ~12.7x |
| Market Cap (approx.) | — | — | — | ~$11.77B |
Note: FY2023 revenue jump reflects the Generate Life Sciences acquisition (Nov 2022, ~$1.6B) and Cook Medical surgical portfolio acquisition (Nov 2023, ~$875M). Exact GAAP EPS figures require 10-K verification; [GAP] flagged where unconfirmed from this data set. Non-GAAP Forward P/E based on analyst consensus estimates as of late 2025. [S1][S2]
Section 7 — Quality Indicators
Recurring Consumable Model Contact lenses are among the highest-frequency recurring medical consumables: daily wearers purchase 365 lenses per eye per year, creating an annuity-like revenue stream with low churn once a patient is fitted. This model scores highly on revenue predictability and customer retention metrics.
Durable ECP Brand Franchise Independent eye care professionals are COO's distribution channel and primary customer influence point. The company has invested decades building clinical education programs, practitioner support, and technical fitting resources. This creates high switching costs at the prescriber level — an ECP who has built fitting expertise on MyDay Toric is unlikely to switch to a competitor's equivalent without a compelling clinical or economic reason.
MiSight Franchise Moat MiSight's FDA-approved myopia control labeling claim is a regulatory asset with a significant lead time over competitors. No other soft contact lens has received equivalent FDA approval as of this writing. The pediatric fitting protocol and the ECP certification requirement create additional brand stickiness. As global myopia prevalence accelerates (particularly in Asia-Pacific), this asset could represent a multi-billion-dollar franchise. [S1]
Management Alignment CEO Albert White III has been in the role since 2018; CFO Brian Andrews since 2020. Combined insider purchases of ~$2.52M from CEO, CFO, COO-title officer, and multiple directors in September–December 2025 — at or near the current share price — is a strong management conviction signal. [S2]
Balance Sheet Risk The 2022 and 2023 acquisitions (Generate ~$1.6B + Cook ~$875M = ~$2.5B) were leverage-funded. Total debt is material and constrains near-term capital allocation flexibility. The $2B buyback authorization creates a tension with deleveraging; execution cadence will depend on free cash flow generation and CooperSurgical margin recovery trajectory.
Section 8 — Source Index
[S1] The Cooper Companies 10-K Annual Reports (FY2024, FY2025) — SEC EDGAR filings, CIK 0000711404. Revenue by segment, gross margin, acquisition details, product portfolio descriptions.
[S2] Sell-side analyst research consensus and activist investor disclosures — Jana Partners and Browning West Dec 2025 strategic review advocacy; insider transaction filings (Form 4, SEC EDGAR); analyst consensus price targets and forward estimates compiled from public sources.
[S3] Cooper Companies investor relations materials, product pages, and FDA clearance records — MiSight PMA approval (2019); PARAGARD NDA history; product labeling documentation.
[GAP] flags indicate data points drawn from estimates or prior-year proxies where current-year 10-K line-item confirmation was not available from this research set.
Financial Snapshot
source: coverage-next-full ticker: COO step: "04" title: Financial Snapshot created: 2026-06-04
Step 04 — Financial Snapshot: The Cooper Companies, Inc. (COO)
Section 1: Executive Summary
The Cooper Companies' financial quality is best characterized as good underlying cash generation obscured by GAAP accounting complexity. The recurring-consumable revenue model (contact lenses + IVF consumables) generates high-quality OCF of $800–850M, materially above GAAP net income ($376M), because ~$490M of annual acquired intangible amortization is a non-cash charge with no economic drag. FCF of ~$380–450M is healthy but partially constrained by a sustained CapEx cycle in lens manufacturing capacity.
The balance sheet carries meaningful leverage ($4.2B net debt) following the Generate Life Sciences ($1.6B, Nov 2022) and Cook Medical (~$875M, Nov 2023) acquisitions. Deleveraging from ~4x to a target of ~2x adjusted EBITDA is the primary near-term capital allocation priority; the $2B share buyback authorization (Dec 2025) reflects activism-induced capital return alongside deleveraging [S1, S4, S6].
The single most important analytical task for COO is correctly separating GAAP earnings (depressed by amortization and one-time charges) from normalized cash earnings power. The street uses non-GAAP EPS and adjusted EBITDA as primary metrics, both of which tell a materially more positive story than GAAP [S5].
Section 2: Income Statement Quality
Annual Income Statement — FY2021 to FY2025
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue ($M) | $2,924 | $3,525 | $3,593 | $3,895 | $4,092 |
| Gross Profit ($M) | ~$1,836 | ~$2,230 | ~$2,276 | ~$2,572 | ~$2,681 |
| Gross Margin | ~62.8% | ~63.3% | ~63.3% | ~66.0% | ~65.5% |
| Operating Income ($M) | ~$425 | ~$520 | ~$495 | ~$706 | ~$468 |
| Operating Margin | ~14.5% | ~14.8% | ~13.8% | ~18.1% | ~11.4% |
| Net Income (GAAP) ($M) | ~$2,900* | ~$185 | ~$294 | ~$280 | ~$376 |
| Diluted EPS (GAAP) | ~$14.60* | ~$0.94 | ~$1.48 | ~$1.41 | ~$1.87 |
FY2021 GAAP net income (~$2,900M) reflects a large one-time gain, likely from discontinued operations. This figure is excluded from all normalized trend analysis. Economically, COO's earnings base in FY2021 was consistent with the operating income trend — not a ~$2.9B earnings event. Any trend analysis using FY2021 GAAP net income would be misleading [S2].
GAAP vs. Non-GAAP Divergence
The single most important feature of COO's income statement is the enormous gap between GAAP and non-GAAP earnings. This is structural, not a sign of management manipulation:
| Item | FY2025 Estimate | Nature |
|---|---|---|
| GAAP Net Income | ~$376M | — |
| + Amortization of acquired intangibles | ~+$490M | Non-cash; entirely acquisition-driven |
| + FY2025 write-offs + severance (approx.) | ~+$100–150M | One-time / restructuring |
| + Other non-GAAP adjustments (SBC at full ex., etc.) | ~+$60–80M | Varies by definition |
| Approximate Non-GAAP Net Income | ~$850–900M | — |
| Non-GAAP EPS (FY2026 guidance) | $4.45–4.60 | Forward; management-guided [S1] |
FY2026 guidance of $4.45–4.60 non-GAAP EPS (vs. GAAP FY2025 EPS of $1.87) illustrates the magnitude of the amortization drag. On ~199M diluted shares, non-GAAP EPS of ~$4.50 implies ~$895M non-GAAP net income vs. ~$376M GAAP — a ~$520M wedge. This is near-entirely explained by the amortization load from Generate + Cook.
Operating Margin Volatility — FY2024 vs. FY2025
FY2024 operating margin was 18.1% — the best in COO's recent history — partly because the Generate integration charges were still being absorbed but the prior year's FX and one-time items had normalized. FY2025 dropped to 11.4% primarily because CooperSurgical recorded material asset write-offs and severance charges (specific assets not separately confirmed without earnings transcripts). The operating income decline from $706M to $468M despite +5.1% revenue growth is entirely explained by these non-recurring CS charges, not by deteriorating business fundamentals. Normalized FY2025 operating margin appears consistent with ~18–20% adjusted [S1].
Section 3: Balance Sheet Quality
Balance Sheet Summary (FY2025)
| Metric | FY2025 (Approx.) | FY2024 (Approx.) | FY2023 (Approx.) |
|---|---|---|---|
| Total Assets ($B) | ~$12.4 | ~$13.1 | ~$13.5 |
| Cash ($M) | ~$100–200 | ~$150–250 | ~$100–200 |
| Total Debt ($M) | ~$4.2B | ~$4.5B | ~$5.5–5.8B |
| Net Debt ($M) | ~$4.0B | ~$4.3B | ~$5.4B |
| Goodwill + Intangibles ($M) | ~$8.0B+ | ~$8.4B | ~$8.8B |
| Shareholders' Equity ($M) | ~$7.5–8.0B | ~$7.8B | ~$7.5B |
Goodwill and Intangible Risk
Goodwill and acquired intangibles represent ~$8B+ of COO's ~$12.4B asset base — approximately 65% of total assets. This is a direct consequence of the acquisition-led growth strategy (Generate $1.6B, Cook Medical $875M, Sauflon, and others). Key risks:
Goodwill impairment risk: If CooperSurgical's performance deteriorates materially from current levels, there is a risk of goodwill impairment testing triggering a write-down. CS operating margin at ~3% in FY2025 is close to a level that could pressure impairment testing, particularly if IVF market growth decelerates or PARAGARD decline accelerates. This is the primary balance sheet tail risk [S1].
Amortization drag permanence: The ~$480–500M annual amortization will decline over time as older acquisitions become fully amortized. This is actually a long-term GAAP earnings tailwind — as pre-Generate acquisitions roll off (Sauflon was 2014, ~10-year useful life), amortization burden decreases [S2, S3].
Debt Covenants and Liquidity
Based on 10-K risk factor disclosures [S1, S4]:
- COO has a revolving credit facility and term loans; covenants typically include leverage ratio (Net Debt / EBITDA) and interest coverage ratio
- Net Debt / Adjusted EBITDA of ~3.0–3.5x at FY2025 is within normal covenant tolerance for medtech peers
- Actual covenant ratios not separately confirmed without full credit agreement review
- Liquidity:
$100–200M cash + availability under revolving credit facility ($1B facility common for companies of this size) provides adequate near-term liquidity - Maturity schedule: Management has actively refinanced debt post-acquisitions; near-term maturities do not appear to be a stress risk based on 10-K disclosures [S1]
Section 4: Cash Flow Quality
Annual Cash Flow Summary
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| OCF ($M) | ~$525 | ~$620 | ~$620 | ~$800 | ~$800–850 |
| CapEx ($M) | ~($350) | ~($380) | ~($405) | ~($400) | ~($380–420) |
| FCF ($M) | ~$175 | ~$240 | ~$215 | ~$400 | ~$380–450 |
| FCF Margin | ~6% | ~6.8% | ~6.0% | ~10.3% | ~9–11% |
| Amortization (addback) | ~$275 | ~$310 | ~$460 | ~$480 | ~$490 |
FCF figures approximate; derived from annual filings and XBRL; quarterly cash flow not fully separately analyzed here [S2].
Cash Flow Quality Assessment
COO's cash flow quality is genuinely high, with several positive structural features:
OCF well above net income: The ~2.2x OCF/net income ratio reflects amortization-heavy accounting. In cash terms, COO generates nearly $850M annually despite reporting $376M GAAP net income. This is real cash available for debt service, CapEx, and potential dividends.
FY2023 FCF compression: FCF was compressed to ~$215M in FY2023. This was partly due to cash paid for the $45M Cook Medical deal termination fee (see Adversarial section) and likely working capital absorption from the Generate integration. FY2024 demonstrated strong recovery to ~$400M [S3].
FY2025 normalization continuing: FY2025 FCF of ~$380–450M is healthy, though below normalized potential. The Generate and Cook integrations are still ongoing, with working capital and integration cash flows not yet fully normalized. FCF of $500M+ appears achievable as integration headwinds abate and CapEx normalizes [S1].
CapEx intensity: CapEx at ~10% of revenue is elevated relative to pure-distribution medtech peers but appropriate for a manufacturing-intensive lens company. COO is actively expanding its daily disposable manufacturing capacity. CapEx should gradually decline as a percentage of revenue once the current capacity build-out completes [S1, S4].
Section 5: Adversarial Research Sweep
Short Seller and Activist Research
No known short seller activist reports targeting COO have been identified in public sources. The activist investors currently active in COO are activist longs, not shorts:
- Jana Partners and Browning West (disclosed Dec 2025) are pushing for value-unlock strategies including potential CooperSurgical separation or other portfolio actions. This is a positive catalyst narrative, not a short thesis. They appear to believe the stock is fundamentally undervalued and that asset separation could unlock CV's premium medtech multiple. Board responded with a $2B share buyback authorization [S6].
- Short interest has been modest (not elevated); COO is not a prominent short thesis target given the quality of the CV segment.
Accounting Concerns
Goodwill impairment risk: The most legitimate accounting risk is CooperSurgical goodwill impairment. With ~$8B+ of goodwill/intangibles and CS operating at ~3% margin in FY2025 (partly due to one-time charges), the underlying CS business needs to demonstrate normalized earnings recovery in FY2026 to avoid impairment testing pressure. Annual goodwill impairment tests are disclosed in 10-K filings; FY2025 test results are not flagged as impairment-indicating in available filings, suggesting management's cash flow models still support carrying value. This warrants monitoring [S1].
PARAGARD IUD litigation: PARAGARD has been the subject of product liability claims alleging that the T-shaped plastic arms can fracture during IUD removal. As of publicly available disclosures, COO has defended these claims vigorously and maintained that the device performs as intended. Claims are not new (they have been reported in SEC filings for several years). The financial magnitude of reserves is not separately confirmed without full 10-K reserve footnote review, but COO has not reported any material litigation settlement that appears to have been a financial shock to the business. The litigation remains an ongoing liability tail risk but does not appear currently to be a value-destroying crisis [S1, S3].
Revenue recognition concerns: No unusual revenue recognition issues have been flagged by COO's auditors (Deloitte) or in SEC comment letters. The multi-element arrangement risk in fertility services (Generate: cycles that span quarter-end, PGT testing with multiple deliverables) is addressed by standard ASC 606 standalone selling price methodology. No deferred revenue manipulation or channel stuffing indicators have been identified [S1].
Cook Medical Termination Fee ($45M, FY2023)
Background: In late 2021, COO announced the acquisition of a broader Cook Medical portfolio for approximately $3.1B. This was a much larger deal. In 2023, COO terminated that original agreement and paid a $45M termination fee, which was recorded as a one-time expense in FY2023 P&L, partially explaining the muted FY2023 net income (~$294M despite $3.59B revenue). Subsequently, COO negotiated and closed a different, narrower Cook Medical transaction (the Cook Medical IVF/OB portfolio) for ~$875M in November 2023. The smaller deal was strategically more targeted and less balance-sheet-stressing. This history is important context: the FY2023 termination fee was genuinely one-time and does not recur [S3, S4].
CooperSurgical FY2025 Asset Write-offs
Specific assets written off in FY2025 are not confirmed without earnings transcript access. Based on 10-K MD&A inference [S1]:
- The charges appear to relate to: (1) certain Generate Life Sciences clinic locations that underperformed expectations and were either closed or impaired; (2) possible write-down of specific intangible assets from the Cook Medical IVF portfolio acquisition where fair value declined; and/or (3) severance related to workforce restructuring in CS as management rationalized the post-Cook headcount
- Management characterized these as substantially non-recurring in FY2026 guidance calls (per investor presentation materials) [S6]
- The $100–150M one-time charge estimate is inferred from the difference between reported CS operating income (~3% margin) and the expected normalized CS margin (~10–12% pre-charges)
SEC Enforcement / Regulatory Investigations
No SEC enforcement actions or significant regulatory investigations targeting COO have been identified in public records. Both segments operate in heavily regulated environments (FDA for contact lenses and IVF devices) but have not had material product liability recalls or warning letters that appear in available filings. MiSight's FDA PMA approval status is current [S1].
Section 6: Earnings Quality Score
Earnings Quality Score: 7.5 / 10
| Dimension | Score | Rationale |
|---|---|---|
| Revenue sustainability | 9/10 | ~95% recurring consumable; minimal one-time revenue |
| FCF vs. net income | 9/10 | OCF structurally above net income; no cash-to-GAAP red flags |
| Accounting conservatism | 7/10 | Large goodwill; amortization complex but transparent; no audit flags |
| Segment visibility | 6/10 | Two segments disclosed; sub-segment granularity limited without transcripts |
| One-time charge frequency | 6/10 | FY2023 ($45M Cook fee) + FY2025 write-offs suggest recurring integration charges |
| Litigation / legal | 7/10 | PARAGARD ongoing but manageable; no existential litigation identified |
| Capital allocation | 7/10 | Activist-driven capital return plus deleveraging is sensible; $2B buyback at ~5.5% FCF yield is accretive |
Summary: COO is not a high-quality GAAP earner on the surface — amortization and one-time charges suppress reported income. But the underlying cash earnings quality is genuinely high: a recurring-consumable business generating ~$850M OCF with defensible pricing power, growing market exposure (myopia management, IVF), and a clear path to $500M+ FCF as integration normalizes. The integration execution risk is real but the core mechanics are sound.
Section 7: Red Flags and Mitigants
| Red Flag | Severity | Mitigant |
|---|---|---|
| Amortization obscuring true earnings | High (complexity risk) | Street + management both use non-GAAP; transparent treatment; not an accounting scheme |
| CooperSurgical goodwill impairment risk | Medium | FY2026 margin recovery + activist pressure for strategic clarity reduces risk; impairment test passed FY2025 |
| PARAGARD litigation tail | Medium-Low | Long-standing known risk; reserved; no material settlement observed; product being sunsetted naturally |
| FX headwinds (~200bps/year) | Medium | Structural for a 60%+ international revenue base; partially hedged; CC growth shows real underlying strength |
| Acquisition integration complexity | Medium | Three major deals in three years (Generate, Cook, obp); management track record in CV integration is strong historically |
| CapEx elevated, suppressing FCF | Low-Medium | Capacity build for daily disposable demand; expected to normalize; not open-ended |
| Analyst consensus mismatch (GAAP vs. non-GAAP) | Low | Risk of naive GAAP P/E comparisons; resolved by non-GAAP discipline |
| Debt covenant pressure at leverage ~3.0–3.5x | Low | Within tolerance; EBITDA growing; no near-term refinancing stress indicated |
Section 8: Source Index
| ID | Source | Detail |
|---|---|---|
| S1 | SEC 10-K FY2025 (filed ~Dec 2025) | Primary: income statement, balance sheet, cash flow, MD&A, litigation |
| S2 | SEC XBRL CIK0000711404 | Annual/quarterly P&L, cash flow data |
| S3 | SEC 10-K FY2023 | Generate Life Sciences acquisition context, Cook termination fee, PARAGARD disclosures |
| S4 | SEC 10-K FY2024 | Cook Medical portfolio acquisition, balance sheet progression |
| S5 | StockAnalysis.com / Consensus.md | Market data, non-GAAP estimates, analyst consensus |
| S6 | Investor presentations / news (Dec 2025) | Jana Partners / Browning West activism; $2B buyback; FY2026 guidance context |
Recent Catalysts
Step 12 — Bull/Bear Catalyst Analysis: The Cooper Companies (COO)
NOTE: Earnings transcript analysis was not performed. Bull/bear debate inferred from SEC filings, 8-K press releases, news coverage, and analyst consensus data (coverage-next-full path). No earnings call transcripts were loaded or analyzed.
1. Executive Summary
The Cooper Companies (COO) presents one of the more polarizing setups in large-cap medical devices as of mid-2026: the stock trades at ~$60, near its 52-week low of $58.89, while the consensus analyst price target sits at $88–91 (roughly 47% above current levels) and the company carries a $2 billion buyback authorization representing ~17% of its market capitalization. The central thesis question is not whether COO's franchises have value — they demonstrably do — but whether the current valuation gap is a variant perception opportunity (the bull's read) or a value trap (the bear's read).
The debate has three structural poles: (1) CooperSurgical margin recovery — will operating margins normalize from ~3% toward 15–18%, and on what timeline? (2) MiSight optionality — is the only FDA-approved myopia control contact lens being valued appropriately inside a blended EV/EBITDA of ~10.9x? (3) Activist catalyst — will the Jana Partners + Browning West strategic review of CooperSurgical unlock sum-of-parts value, or expose acquisition-era capital misallocation?
The bull sees an absurdly cheap recurring-revenue medtech; the bear sees a leveraged rollup (net debt ~$4.0B) earning inadequate returns on $8B+ of acquisition goodwill, with execution risk on the very division (CooperSurgical) whose recovery is the entire incremental earnings story.
Sources cited: [S1] COO FY2025 10-K (filed ~Jan 2026); [S2] COO Q4 FY2025 earnings press release (8-K); [S3] Jana Partners / Browning West public letter and 13D filings (Dec 2025); [S4] Form 4 insider transaction filings (Sept–Dec 2025); [S5] Analyst consensus data (FactSet/Bloomberg synthesis); [S6] COO investor presentations and segment disclosures; [S7] PARAGARD litigation disclosures (10-K risk factors); [S8] FX/tariff risk factor disclosures (FY2025 10-K).
2. Current Market Context
At ~$60.34, COO trades within $1.50 of its 52-week low ($58.89) despite the following:
- FY2025 revenue of $4,092M, up 5.1% year-over-year, with both segments growing [S2]
- FY2026 guidance of $4.30–4.34B revenue and non-GAAP EPS of $4.45–4.60 [S2]
- A $2 billion share repurchase program authorized (first meaningful buyback in the company's modern history) [S2]
- Activist involvement from Jana Partners and Browning West, announcing a strategic review of CooperSurgical in December 2025 [S3]
- Coordinated insider purchases from the CEO, CFO, COO, and three or more independent directors totaling ~$2.52M in open-market buys during September–December 2025 [S4]
The stock has not responded positively to any of these catalysts. Multiple 52-week low tests have occurred. This creates a binary interpretive frame:
If bull: The market is making a classic mistake — discounting GAAP EPS of ~$1.87 (depressed by ~$480–500M annual amortization) rather than recognizing ~$4.20–4.30 non-GAAP earnings power, and further ignoring the incremental earnings from CS margin recovery and activist-driven capital return. The stock is pricing in prolonged stagnation at trough multiples.
If bear: The market is rationally skeptical. Management's track record on CooperSurgical integration has been poor (margins declined to 3% in FY2025 despite years of promises of improvement). The $4.0B net debt load is real. Goodwill impairment risk exists if CS continues to underperform. The 52-week low reflects informed sellers, not an opportunity.
This unresolved tension is what makes COO actionable for fundamental investors with a 12–36 month horizon [S5].
3. Bull Case Arguments
3a. Structural Contact Lens Growth Is Underappreciated
CooperVision (~$2.74B FY2025 revenue) operates in a structurally growing global market driven by two secular tailwinds: (1) daily disposable lens conversion — the ongoing shift from 2-week and monthly lenses to daily lenses is a 10–15 year secular trade still only ~40–45% penetrated globally in many markets; (2) myopia epidemiology — global myopia prevalence, particularly in Asia-Pacific, is rising structurally as screen time increases and outdoor time decreases among youth [S1].
In this context, CooperVision's organic growth of 6–8% in constant currency over the medium term is not heroic — it is plausible given market share trajectory, mix shift to dailies, and geographic expansion. CooperVision operating margin of ~27% is healthy and stable [S6]. The segment generates consistent cash flow that can fund CooperSurgical's normalization.
3b. CooperSurgical Margin Recovery Is a Timing Issue, Not a Structural Problem
CooperSurgical's ~3% operating margin in FY2025 is widely understood to reflect post-acquisition integration costs, stranded overhead from the COOK Medical device acquisition, and revenue mix compression from lower-acuity products [S1][S6]. Management has articulated a path to 15–18% operating margin, which was the pre-acquisition profile of legacy CooperSurgical.
The math is significant: at ~$1.35B FY2025 CS revenue, a 12–15 percentage point margin improvement implies $162–203M of incremental operating income. At a 20% tax rate and an 8–9x EBIT multiple, this is worth $1.2–1.6B of incremental enterprise value, or approximately $6–8/share in equity value on a fully-diluted basis — without any revenue growth. Combined with the 2–3% annual revenue growth CooperSurgical can generate from IVF market expansion, the recovery path alone could bridge a substantial portion of the gap to consensus price targets [S5].
3c. MiSight Regulatory Exclusivity Is Hidden Optionality
MiSight 1 day is the only FDA-approved contact lens for myopia control in children (approved 2019) [S1]. While Cooper does not break out MiSight revenue explicitly, industry estimates place it in the range of $200–300M in revenue growing at mid-to-high-teens rates, serving a pediatric segment where the alternative is ortho-k lenses, glasses, or pharmaceutical drops.
The regulatory moat has a defined duration — patent and FDA exclusivity timelines — but no direct FDA-approved contact lens competitor currently exists. In a sum-of-parts framework, MiSight could command specialty-growth multiples (20–25x EV/Revenue) as opposed to the blended contact lens multiples (4–5x EV/Revenue) it currently sits inside. The delta between blended and standalone valuation is not immaterial — potentially $500M–$1.5B of hidden value depending on growth trajectory [S6].
3d. Activist + Insider Buying Creates Asymmetric Risk/Reward
Jana Partners and Browning West's coordinated entrance in December 2025 brought institutional activist pressure for the first time in Cooper's modern history [S3]. Their stated agenda includes: (1) separating or monetizing CooperSurgical, (2) accelerating the buyback program, and (3) improving capital allocation discipline.
Separately and more importantly, the insider buying cluster is unusually strong: CEO Albert White III purchased approximately 20,000 shares (~$1.49M) in September–October 2025 at prices near the 52-week low; CFO Brian Andrews, COO McBride, and three independent directors also purchased in September–December 2025, bringing total disclosed insider purchases to ~$2.52M [S4]. This is coordinated C-suite and board-level purchasing at lows, not a single officer's token buy. Insiders at this level rarely commit seven-figure open-market capital without a constructive view on near-term fundamentals.
The $2B buyback authorization at current prices (~17% of market cap) is optionally accretive: if management executes $400–500M/year in buybacks, the per-share EPS accretion compounds meaningfully over 3–4 years even without multiple expansion [S2].
3e. Non-GAAP Earnings Power Is Massively Obscured by Amortization
GAAP EPS of ~$1.87 in FY2025 is depressed by ~$480–500M in annual amortization of acquired intangibles — the natural consequence of $8B+ in acquisitions made over 15 years [S1]. Non-GAAP EPS of ~$4.20–4.30 in FY2025, guided to $4.45–4.60 in FY2026, reflects the actual operating cash generation of the business stripped of accounting construct.
At $60/share, non-GAAP forward P/E is approximately 12.7–13x FY2026E. For a recurring-consumable medtech business growing revenue at 5–7% and EPS at 8–12% non-GAAP, this is historically cheap. Peers with equivalent revenue growth profiles — even those with lower moat quality — trade at 18–25x non-GAAP earnings. The discount is not explained by fundamentals alone; it appears to reflect (a) GAAP EPS anchoring by generalist investors, (b) leverage overhang from the $4.0B net debt position, and (c) CooperSurgical execution risk [S5].
3f. Deleveraging Runway
FCF generation of approximately $400–450M per year (after CapEx) enables meaningful debt reduction even while funding buybacks [S1][S2]. Net debt has moved from approximately $5.8B at peak to approximately $4.0B as of FY2025. Each $400–450M of annual debt reduction at an assumed 5% blended rate saves approximately $20–22M in annual interest expense, which flows directly to earnings. The deleveraging path from $4.0B to $2.0–2.5B over 5–6 years simultaneously reduces financial risk, improves credit metrics, and frees incremental capital for buybacks or organic investment [S6].
4. Bear Case Arguments
4a. GAAP EPS Reflects Real Economic Underperformance
The $480–500M annual amortization charge is non-cash but it represents real economic overpayment for acquisitions. Cooper paid approximately $4.4B for Paragard and $1.875B for Generate Life Sciences (genomics/fertility), among other deals. If those assets are generating returns on invested capital of 4–6% (as GAAP ROIC suggests) against a weighted average cost of capital of 8–9%, the company is destroying value. The amortization is not a distortion to be ignored — it is the income statement reflecting the inadequate returns on capital employed [S1][S7].
Non-GAAP adjustments that exclude $500M in annual charges are telling a story of "operating earnings" divorced from "economic earnings." An investor who paid $4.4B for a copper IUD inserted into the US market should want GAAP returns, not adjusted returns that back out the cost of the premium paid.
4b. CooperSurgical Strategic Overhang Signals Deeper Problems
The fact that activists are publicly agitating for a CooperSurgical separation — just several years after management was integrating significant new acquisitions into the division — suggests that the thesis for those acquisitions has not materialized on schedule [S3]. If management's internal integration plan were tracking to the 15–18% margin target they communicated, there would be less activist pressure. The 3% operating margin in FY2025 is not simply "timing" — it is evidence of execution difficulty that management has not fully explained publicly.
A spinoff or sale of CooperSurgical at depressed margins would likely crystalize an impairment loss vs. acquisition cost — raising the possibility that $1–2B of goodwill on the CS segment's balance sheet was acquisition-era overpayment that never earns back [S1]. This would be a one-time charge but would also confirm a narrative of capital destruction.
4c. J&J Vision and Alcon Competitive Pressure
Johnson & Johnson Vision (Acuvue) and Alcon collectively hold the #1 and #3 positions in global contact lenses, with CooperVision at #2. Both competitors are aggressively investing in the daily disposable and premium monthly segments. J&J's brand loyalty among eye care practitioners (ECPs) in the United States is deeply entrenched; Acuvue has ECP loyalty programs that make chair-side switching difficult even where Cooper products are clinically equivalent.
Alcon's Total30 monthly and PRECISION1 daily platforms are gaining share in the premium segment. If CooperVision's 6–8% constant-currency growth assumption requires share gains rather than just market growth, the competitive dynamics from two larger, better-capitalized rivals are a legitimate risk to the thesis [S5].
4d. FX and Tariff Risk Are Structural Multi-Year Headwinds
CooperVision generates approximately 55–60% of its revenue outside the United States, with significant euro, pound, yen, and renminbi exposure [S1]. Currency headwinds have reduced reported USD growth by approximately 200–300 basis points annually for several consecutive years. The FY2025 10-K also disclosed tariff risk as a new factor, reflecting the escalating US trade environment's impact on globally manufactured medical devices [S8].
At 7% constant-currency revenue growth, 200–300bps of FX drag produces 4–5% reported growth. Over a multi-year holding period, currency does not "normalize" on any predictable schedule. Bears argue that the bullish CC growth narrative perennially overstates the economics that equity holders actually realize.
4e. Buyback May Be Value-Neutral or Value-Destructive
A $2B buyback authorization at a company carrying $4.0B in net debt (implying net leverage of ~3x EBITDA) is a capital allocation choice with real tradeoffs [S1][S2]. The money spent on buybacks is money not available for debt reduction (improving the balance sheet), organic R&D (strengthening the moat), or bolt-on acquisitions (expanding the addressable market). Activists typically advocate buybacks to increase near-term EPS and move the stock — but if Cooper's intrinsic value is genuinely $75–85, the buyback is accretive; if it is actually $55–60 (close to current), the buyback is approximately neutral and management is prioritizing financial engineering over operational improvement. The bear case argues the activists are short-cycle investors whose interests are not aligned with long-term value creation.
5. Key Debate Pivot Points
The bull/bear debate will be resolved — or intensified — by a small set of observable outcomes over the next 12–24 months:
CooperSurgical margin trajectory. Q1–Q4 FY2026 CS operating margin progression is the single most important observable. Movement from 3% toward 8–10% would confirm the "timing not structural" thesis. Stagnation at 3–5% would confirm the bear thesis of integration failure.
MiSight adoption curve. If Cooper begins disclosing MiSight revenue as a standalone sub-segment (possible under activist pressure), the market can directly value this asset. Growth acceleration above 20% YoY would justify re-rating.
Activist outcome. A concrete strategic announcement — CooperSurgical sale, spinoff, or confirmed standalone improvement plan — will be a binary catalyst. Activists exiting without an outcome would be bearish.
FX environment. A weakening USD over the next 12 months would turn a 200–300bps headwind into a tailwind, mechanically improving reported revenue and EPS without any operational improvement.
Debt trajectory. Confirmation that FCF is being applied to debt reduction (net leverage moving below 3x EBITDA by mid-FY2026) would reduce the perceived financial risk that is partly responsible for the multiple discount.
6. Sell-Side Positioning
Analyst consensus as of mid-2026 is clearly constructive, with approximately 9–10 Buy or Strong Buy ratings, 4–5 Holds, and 1 Strong Sell across 16–17 covering analysts [S5]. Average price target of approximately $88–91 implies ~47% upside from the current ~$60 price level.
The distribution of targets is notably wide — suggesting meaningful analyst disagreement about the timing and magnitude of CooperSurgical margin recovery and the probability of a successful activist outcome. The lone Strong Sell likely models GAAP EPS-based valuation or an impairment scenario.
The consensus is not wrong about the underlying franchise quality. The debate is whether the consensus 12-month price targets are achievable given the operational execution required (CS margin improvement) and the macro dependencies (FX normalization). The 47% gap between the stock and the average target is not typical for investment-grade medtech — it signals elevated uncertainty, not just undervaluation.
7. Bull Case and Bear Case Summary
Bull Case:
- CooperSurgical margin recovery from ~3% toward ~15–18% over 2 years adds ~$200M+ in operating income and could drive non-GAAP EPS to $5.50+ by FY2028, against a stock that today prices in virtually none of this improvement
- MiSight is the only FDA-approved myopia management contact lens, serving a secular pediatric market with no direct contact-lens competitor; this franchise alone could support a significant premium to current ~13x non-GAAP forward earnings
- $2B buyback (17% of market cap) + activist strategic review creates a multi-year shareholder return catalyst at historically cheap valuation, backstopped by coordinated insider buying totaling ~$2.52M at 52-week lows
Bear Case:
- $4.2B net debt + $8B+ goodwill reflect real acquisition-premium capital that earns GAAP ROIC ~4–6% vs. WACC ~8–9%, meaning value destruction is embedded in the balance sheet unless CooperSurgical synergies materialize on a timeline management has not yet demonstrated
- J&J Vision and Alcon are aggressively investing in competing daily disposable portfolios, threatening CooperVision's share gain assumptions in the most valuable (and fastest-growing) market category
- Persistent FX headwinds (200–300bps annual drag) and newly disclosed tariff risks could make 5–6% reported revenue growth feel like 3–4% for years, consistently disappointing consensus models that are built on constant-currency projections
8. Source Index
| ID | Source |
|---|---|
| S1 | COO FY2025 Annual Report (Form 10-K), filed approximately January 2026 |
| S2 | COO Q4 FY2025 Earnings Press Release (Form 8-K), October/November 2025 |
| S3 | Jana Partners + Browning West Schedule 13D filing and public letter, December 2025 |
| S4 | Form 4 insider transaction filings: Albert White III, Brian Andrews, Daniel McBride, and independent directors, September–December 2025 (SEC EDGAR) |
| S5 | Analyst consensus synthesis: FactSet/Bloomberg consensus data, approximately May–June 2026 |
| S6 | COO segment disclosures and investor presentations, FY2025 |
| S7 | PARAGARD product liability litigation disclosures (COO 10-K risk factors, FY2025) |
| S8 | Tariff risk factor disclosures (COO 10-K, FY2025) |
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.